Mustafa Özdoğan, MD X Hesabı İstatistikleri

X Hesabı

http://x.com/ozdogan_md

Son Kontrol : 13.05.2026

Takipçisi 6.668

Takip Edilen 1.028

Sektör

Tweetler	Beğeni	Retweet	Etkileşim
#zenocutuzumab marks a new molecular chapter in cholangiocarcinoma. #FDA approval: May 8, 2026 This is the first approved targeted therapy for NRG1 fusion–positive cholangiocarcinoma — a very rare but actionable subgroup. https://t.co/K6kyIEa6FE	6	5	%0,42
ORCHESTRA is an important negative phase 3 trial in metastatic colorectal cancer. In patients with multiorgan mCRC responding to induction chemotherapy, adding aggressive tumor debulking did not significantly improve survival: 🔗...	0	0	%0,00
Can we deintensify RT in HPV+ Oropharyngeal Cancer? A new cohort study shows that deintensified 60 Gy chemoradiotherapy is associated with a low 5-year locoregional recurrence of 3.4% and an overall survival exceeding 90% in favorable-risk...	3	1	%0,10

Tweetler	Tarih	Beğeni	Retweet	Etkileşim

Tweetler	Tarih	Beğeni	Retweet	Yorum	Görüntülenme

Takipçi : 6.668

Web sitesi : https://t.co/FcXlIA9hsE

Kullanıcı : ozdogan_md

Tanıtım :

Sayfa ile ilgili istek ve şikayetleriniz için aşağıdaki formu kullanabilirsiniz.